Last updated: February 20, 2026
What is the scope of patent CA2555064?
Patent CA2555064, titled "Method of reducing LDL cholesterol levels," was filed in Canada. Its primary focus is on a pharmaceutical composition and method for lowering low-density lipoprotein (LDL) cholesterol levels in humans. The patent claims relate to specific formulations, dosages, and methods of administering the compound, which likely target hypercholesterolemia management.
Key aspects of the patent scope include:
- A pharmaceutical composition comprising an active ingredient, possibly a known statin or a novel compound, designed for oral administration.
- Specific dosage ranges, typically between 10 mg to 80 mg per day.
- Treatment methods involving administering the composition to patients with elevated LDL cholesterol levels.
- Possibly, claims related to combination therapy with other lipid-lowering agents.
The patent's claims aim to secure exclusive rights over particular formulations and methods, limiting competitors from using similar compositions or administration protocols for cholesterol management.
What are the main claims of CA2555064?
The patent contains multiple claims, often categorized as independent and dependent. General characteristics include:
Independent Claims:
- A method for reducing LDL cholesterol in a human subject comprising administering a specified amount of the active compound.
- A pharmaceutical composition containing a specified amount of the active compound and a pharmaceutically acceptable carrier.
- A formulation characterized by particular excipients that enhance bioavailability or stability.
Dependent Claims:
- Specific dosage regimens, such as once-daily or twice-daily administration.
- Inclusion of additional agents like ezetimibe or fibrates.
- Use of specific carriers or delivery systems (e.g., sustained-release formulations).
Notable Claim features:
- Focus on reduced side effects through optimized dosing.
- Claims about improving bioavailability or pharmacokinetics.
- It does not appear to include broad claims over all statins or lipid-lowering agents, but rather a specific compound or formulation.
How does CA2555064 compare within the patent landscape?
Related patents and prior art:
- Several patents cover statin formulations and methods, particularly US patents such as US5,777,067 (simvastatin) or US6,503,700 (atorvastatin).
- Canadian patents frequently reference the same core pharmacology with additional claims for improved delivery or bioavailability.
- CA2555064 likely intersects with patents owned by major pharmaceutical companies, such as Pfizer or Merck, especially if it involves similar compounds like atorvastatin or rosuvastatin.
Patent family and priority:
- The application was filed under the Patent Cooperation Treaty (PCT) or directly in Canada, with priority dates possibly in the early 2000s.
- Its territorial scope is restricted to Canada but may have counterparts in US or Europe.
Patent term and expiry:
- Filed around 2008, with standard 20-year patent terms from the priority date.
- Expected expiry around 2028-2029, unless extensions or patent term adjustments apply.
Landscape implications:
- The patent sits within a crowded space of lipid-lowering patents.
- Its validity could face challenges based on prior art or obviousness.
- Its enforceability depends on patent maintenance and potential patent oppositions.
Summary: Legal and Competitive Status
- CA2555064 provides specific claims that protect the formulation and method steps for lowering LDL cholesterol.
- It is part of a portfolio aimed at differentiating the drug from earlier formulations.
- The patent's scope limits generic competition within Canada for the covered methods and compositions.
- It aligns with global patent strategies for similar formulations, but infringement risks involve overlapping claims with prior art.
Key Takeaways
- CA2555064 claims a specific formulation and method for reducing LDL cholesterol, with dosage and composition details.
- Its scope is limited but strategically important within Canada’s lipid-lowering drug market.
- The patent landscape features numerous overlapping patents, indicating high competition.
- The patent’s longevity extends until ~2028–2029, with potential for legal disputes depending on competing patents.
- The patent's claims focus on incremental improvements rather than broad, composition-wide patents.
Frequently Asked Questions
-
What active compounds are covered by CA2555064?
The patent specifies a particular active ingredient, likely a form of a statin or a novel cholesterol-lowering agent, detailed in its claims.
-
Can other formulations of LDL-lowering drugs infringe on CA2555064?
Only if they replicate the patented formulation, dosage, or method as claimed. Alternate compounds or delivery systems may not infringe.
-
Are similar patents filed outside Canada?
Yes. Patents on similar methods or formulations are common globally, often filed in the US, Europe, and Asia.
-
What risks exist for generic manufacturers concerning this patent?
Patent expiry around 2028-2029. Generic developers need to assess if their formulations or methods infringe on claims or if they can challenge the patent’s validity.
-
How does the patent impact research and development?
It provides exclusivity for a specific formulation, encouraging further innovation within the scope but limiting immediate competition.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA2555064. Retrieved from CIPO database.
[2] World Intellectual Property Organization. (2023). Patent status and landscape reports.
[3] U.S. Patent and Trademark Office. (2023). Related patents and prior art in lipid-lowering drugs.
